The aim of this study is to clarify the clinicopathologic characteristics of adolescent leukemia in Japan by retrospective analysis. Patients with acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS), consecutively diagnosed from 1986 to 1999, were enrolled. A total of 3856 patients from 1 to 15 years of age and 1803 patients from 15 to 29 years of age were eligible for this study. Demographically, the frequency of AML found was almost constant during the teenage years, whereas the frequency of ALL gradually decreased. The relative frequency of CML and MDS apparently started to increase in patients in their late teens. The relative frequency of M3 and t(15;17) gradually increased during adolescence. Among patients aged 1 to 4 years, M7 was the most frequent FAB subtype. Among patients aged 5 to 9 years, M2 and t(8;21) was the most frequent subtype. The percentage of T cell ALL increased in patients 5 to 9 years old, reaching 31.2% in the 20-to 24-year-old age group. The percentage of patients with hyperdiploidy over 50 chromosomes was highest (17.0%) in patients aged 1 to 4 and decreased to 3.9% in the older teens. The percentage of patients with the Ph 1 chromosome increased from 9.9% in teens to 30.0% in patients in their late twenties. When comparing event-free survival (EFS) rates for ALL according to age, the estimated 7-year EFS rate was highest for patients aged 1 to 9 years (65.9%) and intermediate for patients aged 10 to 15 years (48.4%). However, the EFS rate was significantly worse for patients aged 15 to 19 years (19.4%) and 20 to 29 years (17.0%) (P = 0.024). On the other hand, the EFS rate for AML decreased with increasing age, although without statistical significance. The overall survival rates are approximate among all age groups. The results of the study indicate that there are considerable variations in biologic features of leukemia between children and young adults. The prognosis for adolescent leukemia may be improved by introducing pediatric trials, which take into account the prognostic biological features. Leukemia (2001Leukemia ( ) 15, 1256Leukemia ( -1261 
Introduction
Acute lymphoblastic leukemia (ALL) is a major subtype of leukemia in children, whereas acute myelogenous leukemia (AML) is as common in adults. It is well known that ALL is favorable in children, but not in adults. 1, 2 Although clinicopathologic data are essential to determine the appropriate treatment for adolescents with leukemia, such data are scanty in Japan because adolescents younger than 16 years of age visit pediatricians and those older than 15 years of age see internists with limited collaboration among the physicians. The aim of this study is to clarify the clinicopathologic characteristics of adolescent leukemia in Japan by retrospective analysis.
Patients and methods
Patients with ALL, AML, chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS), consecutively diagnosed from 1986 to 1999 or from 1990 to 1999 in some institutes for adults, were enrolled in this study. To characterize the adolescents (aged 10 to 19 years) with leukemia, patients aged 1 to 9 years and 20 to 29 years from the same institutes were also analyzed for comparison purposes. Infant leukemia was excluded from this study because of its biological differences.
Data on children younger than 16 years of age were obtained from the 57 institutes participating in the Koseisho Study Group for the Treatment of Intractable or Secondary Leukemia in Children (KSG), conducted by Tsukimoto, one of the authors. Data on young adults over 15 year of age were obtained from the 113 institutes participating in the Japan Adult Leukemia Study Group (JALSG) conducted by R Ohno, one of the authors. Geographic distributions of the patients in two data sources, KSG and JALSG were 3.4% and 3.3% in Hokkaido, 6.0% and 2.7% in Tohoku, 44.1% and 37.0% in Kanto, 19.2% and 22.6% in Chubu, 16.2% and 16.8% in Kansai, 5.9% and 6.8% in ChuShikoku, and 5.1% and 10.8% in Kyushu, respectively. The differences in percentages from the two sources were quite large for Tohoku, Kanto and Kyushu. Presumably treatment centers in Kyushu were under-represented in the KSG and those in Tohoku and Kanto were under-represented in JALSG.
In total, 3856 patients from 1 to 15 years of age (male-tofemale ratio: 1.33) and 1803 patients from 15 to 29 years of age (male-to-female ratio: 1.28) were eligible for this study. Patients were divided into groups at 5-year age intervals with age 0 omitted. In the analysis of survival, the patients aged 15 years treated at pediatric institutes were assigned in the 10-15 year group, because treatment strategy was different between pediatric and adult trials, as described below.
Morphologic diagnosis according to French-AmericanBritish classification, 3 immunophenotyping, and karyotypic analysis were performed locally. Diagnosis of M0 appeared after 1991. 4 Mixed lineage leukemia including biphenotypic leukemia and pro-B cell ALL were assigned to others, because their definitions were not standardized among the institutions.
Survival data for ALL and AML were collected for 3345 out of 3664 patients from 1 to 15 years of age and for 794 of 1348 patients from 15 to 29 years of age. Treatment was variable. Children with leukemia were treated by local protocols, 5, 6 and the young adults were treated by JALSG protocols. [7] [8] [9] Differences in treatment strategy for ALL were mainly in the early phase of treatment. In the early phase of pediatric trials for ALL, 5, 6 the induction therapy consisted of multiple doses of Iasparaginase (ASP) in 2 to 3 weeks, weekly vincristine (VCR), 28 days of prednisolone (PSL), daunorubicin or pirarubicin, and/or cyclophosphamide (CPM). Then, the consolidation therapy with cytarabine (CA), 6-mercaptopurine and CPM was followed by sanctuary therapy with high-dose methotrexate (MTX), intrathecal medication and/or cranial irradiation, and reinduction therapy. In early phase of adult trials for ALL, 8 The induction therapy consisted of limited doses of ASP in 1 week, VCR, 10 to 14 days of PSL and doxorubicin. Then, the blockconsolidation therapy including mainly CA, etoposide and mitoxantrone or acrarubicine without high-dose MTX was rotated. No reinduction therapy was instituted. Survival data for CML and MDS have been separately analyzed in pediatric series. 10, 11 Estimates of the overall survival rate and the event-free survival (EFS) rate was calculated using the Kaplan-Meier method. As the event endpoint, we considered induction failure, relapse, or death, whichever occurred first. In the patients who did not achieve complete remission in 5 weeks, the event date was considered to be day 1. Patients with hematopoietic stem cell transplantation in the first remission were censored at the date of transplant in the EFS analysis. The median observation period for survivors was 65 months (range: 1-151 months). Statistical analysis was performed with Statview 5.0 software (Abacus Concepts, Inc., San Diego, CA, USA).
Results

Distribution of subtypes of leukemia
The distribution of ALL, AML, and CML including juvenile myelomonocytic leukemia and MDS, according to age group is shown in Table 1 . A predisposition toward ALL in the 1-to 4-year-old group, with a peak incidence at age 3, was found. The proportion of ALL among leukemia cases gradually decreased, and the same frequency as that of AML was seen in the late teen years. The relative frequency of CML and MDS apparently started to increase in the late teen years, to 8.3% and 5.3%, respectively. The frequency of Down's syndrome in ALL was 1.1% and 1.2% of the KSG and JALSG series, respectively. On the other hand, Down's syndrome in AML was exclusively found in the 1-to 4-year-old group, corresponding to 19.9% of this group.
In Japan, 50% of 15-year-old patients visit pediatricians and 50% visit internists. Therefore, by normalizing the number of patients aged 15 to 19 years according to the ratio of the number of 15-year-old patients of JALSG data to that of KSG data, a comparison of the frequency of patients in each teen age would be possible ( Table 2 ). The results suggested that the frequency of AML was almost constant during the teen years, whereas the frequency of ALL was gradually decreased. 
Distribution of AML subtypes
The distribution of the FAB subtypes and karyotypes of AML are shown in Table 3 . Interestingly, M3 and t(15;17) gradually increased in adolescents, slightly exceeding 20% among patients in their twenties. Among patients aged 1 to 4 years, M7 was the most frequent FAB subtype, making up almost one-third of the incidences, half of which were associated with Down syndrome, corresponding to 93.8% of AML with Down syndrome. A relatively higher incidence of M5 and lower incidences of M1 and M2 were found among patients aged 1 to 4 years than among the other age groups. On the other hand, M2 and t(8;21) were the most frequent subtypes among patients aged 5 to 9 years, making up almost half of the incidences.
Characteristics of clinical features in ALL
With regard to clinical features for ALL, the relative frequency according to age was compared, as shown in Table 4 . In FAB subtypes, a predominance of the L1 subtype in the patients aged 1 to 4 years was found. The relative proportion of L1 gradually decreased, and the frequency of L1 and L2 was reversed in the late teen years. With regard to the white blood cell count at diagnosis (WBC), the number of patients with a WBC less than 10 × 10 9 /l was highest in all age groups. The relative frequency of patients with hyperleukocytosis (WBC у 100 × 10 9 /l) was relatively constant in the patients between the ages of 5 and 29 years. With regard to immunophenotype, the relative frequency of patients with common ALL was highest in all age groups, but gradually decreased with age. The relative frequency of T cell ALL was gradually increased, peaking at 20 to 24 years of age. With regard to karyotype, the relative frequency of patients with hyperdiploidy over 50 chromosomes was highest (17.0%) in the patients aged 1 to 4 years, decreasing to 3.9% in the older teens. On the other hand, the frequency of patients with the Ph 1 chromosome increased from 10.3% in the teens to 30.0% in the late twenties. The relative frequency of hypodiploidy seemed to be gradually increasing with age. The frequency of t(1;19) in adolescents was about 5%, which was slightly higher than the other age groups. The frequency of 11q23 abnormalities was low and variable.
Survival
When comparing the EFS rate for ALL according to the age, the estimated 7-year EFS rate was the highest for the patients aged 1 to 9 years (65.9%) and moderate for patients aged 10 to 15 years (48.4%). However, it was significantly worse for patients aged 15 to 19 years and 20 to 29 years, 19.4% and 17.0% respectively (Figure 1a , P = 0.024). The overall survival rate according to age was consistent with the EFS rate ( Figure  1b) . On the other hand, for the EFS rate for AML, the survival rate decreased without statistical significance as the patient's age increased. Overall survival rates are approximate among all age groups, probably because certain patients with AML were successfully treated with bone marrow transplantation in first remission (Figure 2a and b) . Table 2 Distribution of leukemia subtypes according to age (2) A g e 
Numbers in parentheses are normalized by the ratio of the number of age 15 years. 
Discussion
A clinicopathologic profile of leukemia in Japanese children and young adults was reviewed to clarify the characteristics of adolescent leukemia in this study. Although this is not a population-based study, the patients were from the principal hospitals in Japan and seemed to be representative of the population examined. The overall frequency of leukemia was the highest in the patients under 4 years of age and gradually decreased during adolescents. Then, it was constant in their twenties. As shown in a study conducted in the USA, 2 the frequency of ALL decreased and that of AML remained stable in adolescents, resulting in an inversion of the frequency of ALL and AML in late adolescence. In addition, the frequency of CML and MDS started to increase in late adolescence.
In AML, the profile pattern of FAB subtypes was found to be different among the age groups. In adolescents, M2, M3, and M1 were the three leading subtypes in terms of relative frequency, whereas M7, M2, and M5 were most common in the 1-to 4-year-old group. M2 was half of the patients aged 5 to 9 years. The relative frequency of the M3 subtype gradually increased in adolescents, making up 20% of AML cases in older teens. It was consistent to the frequency of t(15;17). In Caucasians, this frequency was low and constant in adults, 12 except among Latinos 13 and Italians. 14 M7 was found to be the major subtype for patients aged 1 to 5 years; half of these cases were associated with Down syndrome, which has been recognized to have a high frequency with M7 AML in patients under age 3 years in Japan 15 and the USA. 16 Another half of M7 was not associated with Down syndrome. M7 AML without Down syndrome has also been recognized to affect young children. 13 In the AML-BFM Study Group, there was a high Figure 1 (a) Event-free survival curves for patients with ALL using the Kaplan-Meier method according to age group. Seven-year EFS rates were 65.9 ± 1.2% for 1 to 9 years of age (n = 1872), 48.4 ± 2.4% for 10 to 15 years of age (n = 587), 19.4 ± 4.7% for 15 to 19 years of age (n = 180), 17.0 ± 3.4% for 20 to 29 years of age (n = 215), respectively. (b) Overall survival curves for patients with ALL using the Kaplan-Meier method according to age group. Seven-year overall survival rates were 79.2 ± 1.0% for 1 to 9 years of age (n = 1872), 56.6 ± 2.4% for 10 to 15 years of age (n = 587), 36.7 ± 4.9% for 15 to 19 years of age (n = 180), and 34.7 ± 4.1% for 20 to 29 years of age (n = 215).
frequency of M5 (49%) and M7 (13%) among children under 2 years of age with AML; 17 the M7 incidence rate was lower than that in Japan, indicating a possible geographic heterogeneity. 18 These characteristic distribution patterns of FAB subtypes may help to clarify the etiology of AML. On the other hand, In FAB subtypes of ALL, the incidence of L1 and L2 was abruptly reversed in the late teen years. The different patterns of FAB subtypes of ALL in two series may be due to the differences of application of FAB diagnostic criteria between internists and pediatricians in Japan.
In ALL, the relative frequency of T cell ALL was gradually increased, peaking at 20 to 25 years of age. The frequency of T cell ALL, which may reflect geographic differences in Japan, 6 was slightly lower in Japanese than in Caucasians. 19 With regard to genetic features, the frequency of hyperdiploidy more than 50 chromosomes decreased in adolescent leukemia. On the other hand, the proportion of ALL patients positive for the Philadelphia chromosome increased with age.
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Figure 2
(a) Event-free survival curves for patients with AML using the Kaplan-Meier method according to age group. Seven-year EFS rates were 43.1 ± 2.4% for 1 to 9 years of age (n = 559), 34.3 ± 3.4% for 10 to 15 years of age (n = 327), 32.0 ± 4.3% for 15 to 19 years of age (n = 150), and 25.6 ± 3.3% for 20 to 29 years of age (n = 249). (b) Overall survival curves for patients with AML using the KaplanMeier method according to age group. Seven-year overall survival rates were 58.1 ± 2.3% for 1 to 9 years of age (n = 559), 54.8 ± 3.2% for 10 to 15 years of age (n = 327), 53.5 ± 4.3% for 15 to 19 years of age (n = 150), and 51.6 ± 3.7% for 20 to 29 years of age (n = 249).
These figures are consistent with those provided in previous reports. 20, 21 Recently, TEL/AML1 translocation was identified in childhood ALL and was deemed relevant to prognosis. 22, 23 TEL/AML1 translocation is exclusively expressed in ALL patients between 1 and 5 years of age and decreases with age. 22 It is rare in ALL patients older than 15 years. In general, compared to children, adults with ALL have lower induction rates and substantially poorer long-term survival rates. 2 In our analysis, the prognosis of patients aged 15 to 29 years was significantly worse than that of younger patients. The difference of prognosis between adults and children has been attributed to differences in disease biology. That is a higher incidence in adults of genetic abnormalities associated with poor prognoses, especially the Ph1 chromosome, and a lower incidence in adults of those with favorable prognoses, such as hyperdiploidy and TEL/AML1. However, as only 20% of teenage patients have these genetic abnormalities, they cannot explain everything. On the other hand, the difference in treatment approaches between pediatric and adult trials may also be a contributing factor in the differing prognoses. With treatment based on pediatric protocols in adult ALL, the outcome in older teens improved, becoming equivalent to that of younger teens. 24, 25 Indeed, as biological differences among adolescent ALL cases were relatively small in our study, a cooperative study in this field in Japan could improve the outcome for adolescent ALL patients. Moreover, further investigations to reveal unknown factors associated with outcome are needed in order to tailor the treatments.
In the patients with AML, the differences in induction rates and rates of long-term survival were relatively small between children and young adults in our study. Such small differences could have been due to similar treatment approaches using cytarabine, etoposide, and anthracyclines, as well as the small biological differences among the ages. However, the incidence of the FLT3 mutation, reported to be a poor prognostic factor in AML, 26 is lower in children than in adults, 27 a fact that may contribute to the favorable EFS rate of children with AML.
In conclusion, there are considerable variations in the biological features of leukemia between children and young adults. The prognosis for adolescent leukemia may be improved by introducing pediatric trials that take into account the prognostic biological features.
